Alexander Volodarskiy

Alexander Volodarskiy

Auto-generated profile, based on publicly available information

Alexander Volodarskiy

NewYork-Presbyterian in Queens, 56-45 Main St, New York, New York, 11355, United States

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
TPTimothy J. Poterucha
Timothy J. Poterucha
LJLinyuan Jing
Linyuan Jing
RRRamon Pimentel Ricart
Ramon Pimentel Ricart
MAMichael Adjei-Mosi
Michael Adjei-Mosi
JFJoshua Finer
Joshua Finer
PEPierre Elias
Pierre Elias
Early detection of structural heart disease is critical to improving outcomes, but widespread screening remains limited by the cost and accessibility of imaging tools such as echocardiography1,2. Recent advances in machine learning applied to heart rhythm recordings have shown promise in identifying disease3,4, although previous work has been limited by development in narrow populations or targeting only select heart conditions5. Here we introduce a deep learning model, EchoNext, trained on more than 1 million heart rhythm and imaging records across a large and diverse health system to detect many forms of structural heart disease. The model demonstrated high diagnostic accuracy in internal and external validation, outperforming cardiologists in a controlled evaluation and showing consistent performance across different care settings and racial and/or ethnic groups. The models were prospectively evaluated in a clinical trial of patients without previous cardiac imaging, successfully identifying previously undiagnosed heart disease. These findings support the potential of artificial intelligence to expand access to heart disease screening at scale. To enable further development and transparency, we have publicly released model weights and a large, annotated dataset linking heart rhythm data to imaging-based diagnoses.

1 September 2016 in The American Journal of Medicine
Verified
Journal Article
Closed access
SHSean P. Heffron
Sean P. Heffron
APAmar Parikh
Amar Parikh
AVAlexandar Volodarskiy
Alexandar Volodarskiy
CRChristine Ren-Fielding
Christine Ren-Fielding
ASArthur Schwartzbard
Arthur Schwartzbard
SBSripal Bangalore
Sripal Bangalore

11 November 2014 in BMJ
Verified
Journal Article
Open access
PDF file
SBSripal Bangalore
Sripal Bangalore
BTBora Toklu
Bora Toklu
AKAnupam Kotwal
Anupam Kotwal
AVAlexander Volodarskiy
Alexander Volodarskiy
SSSahil Sharma
Sahil Sharma
FFFrederick Feit
Frederick Feit
Objectives To investigate the relative benefits of unfractionated heparin, low molecular weight heparin(LMWH), fondaparinux, and bivalirudin as treatment options for patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI). Design Mixed treatment comparison and direct comparison meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. Data sources and study selection A search of Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) for randomized trials comparing unfractionated heparin plus glycoprotein IIb/IIIa inhibitor(GpIIb/IIIa inhibitor), unfractionated heparin, bivalirudin, fondaparinux, or LMWH plus GpIIb/IIIa inhibitor for patients undergoing primary PCI. Outcomes The primary efficacy outcome was short term (in hospital or within 30 days) major adverse cardiovascular event; the primary safety outcome was short term major bleeding. Results We identified 22 randomized trials that enrolled 22 434 patients. In the mixed treatment comparison models, when compared with unfractionated heparin plus GpIIb/IIIa inhibitor, unfractionated heparin was associated with a higher risk of major adverse cardiovascular events (relative risk 1.49 (95% confidence interval 1.21 to 1.84), as were bivalirudin (relative risk 1.34 (1.01 to 1.78)) and fondaparinux (1.78 (1.01 to 3.14)). LMWH plus GpIIb/IIIa inhibitor showed highest treatment efficacy, followed (in order) by unfractionated heparin plus GpIIb/IIIa inhibitor, bivalirudin, unfractionated heparin, and fondaparinux. Bivalirudin was associated with lower major bleeding risk compared with unfractionated heparin plus GpIIb/IIIa inhibitor (relative risk 0.47 (0.30 to 0.74)) or unfractionated heparin (0.58 (0.37 to 0.90)). Bivalirudin, followed by unfractionated heparin, LMWH plus GpIIb/IIIa inhibitor, unfractionated heparin plus GpIIb/IIIa inhibitor, and fondaparinux were the hierarchy for treatment safety. Results were similar in direct comparison meta-analyses: bivalirudin was associated with a 39%, 44%, and 65% higher risk of myocardial infarction, urgent revascularization, and stent thrombosis respectively when compared with unfractionated heparin with or without GpIIb/IIIa inhibitor. However, bivalirudin was associated with a 48% lower risk of major bleeding compared with unfractionated heparin plus GpIIb/IIIa inhibitor and 32% lower compared with unfractionated heparin alone. Conclusions In patients undergoing primary PCI, unfractionated heparin plus GpIIb/IIIa inhibitor and LMWH plus GpIIb/IIIa inhibitor were most efficacious, with the lowest rate of major adverse cardiovascular events, whereas bivalirudin was safest, with the lowest bleeding. These relationships should be considered in selecting anticoagulant therapies in patients undergoing primary PCI.

21 August 2012 in Heart
Verified
Journal Article
Closed access
PDF file
SBSripal Bangalore
Sripal Bangalore
SKSunil Kumar
Sunil Kumar
AVAlexander Volodarskiy
Alexander Volodarskiy
FMFranz H Messerli
Franz H Messerli
Context Most guidelines for treatment of hypertension including the Joint National Committee-7 recommend a blood pressure (BP) goal of <140/90 mm Hg for hypertensive patients and a more aggressive goal of <130/80 mm Hg for patients with coronary artery disease (CAD), based largely on expert consensus. Objective To evaluate the BP targets in patients with CAD Data Sources PUBMED, EMBASE and CENTRAL Study Selection: Randomised clinical trials (RCTs) of antihypertensive therapy in patients with CAD, enrolling at least 100 patients, with achieved systolic pressure of <=135 mm Hg in the ‘intensive BP’ group and <=140 mm Hg in the ‘standard BP’ group with follow-up for at least 1 year and evaluating cardiovascular outcomes. Data Extraction The following efficacy outcomes were extracted- all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, angina pectoris, heart failure and revascularisation. Results We identified 15 RCTs enrolling 66 504 participants with 276 328 patient-years of follow-up. Intensive BP group (≤135 mm Hg) was associated with a 15% decrease in heart failure rate and 10% decrease in stroke rate, driven largely by trials with a more intensive BP group (≤130 mm Hg), with similar outcomes for death and cardiovascular death and was associated with a 105% increase in the risk of hypotension. More intensive BP group (≤130 mm Hg) was also associated with a reduction in myocardial infarction and angina pectoris. The results were similar in a Bayesian random effects model. In addition, lower seemed to be better (based on regression analysis) for the outcomes of myocardial infarction, stroke, heart failure and perhaps angina. Conclusions The present body of evidence suggests that in patients with CAD, intensive systolic BP control to ≤135 mm Hg and possibly to ≤130 mm Hg is associated with a modest reduction in stroke and heart failure but at the expense of hypotension. Lower was better, although not consistently so for myocardial infarction, stroke, heart failure and perhaps angina. Further trials are needed to prove these findings.

1 December 2016 in The American Journal of Medicine
Verified
Journal Article
Closed access
AVAlexander Volodarskiy
Alexander Volodarskiy
SKSunil Kumar
Sunil Kumar
SAShyam Amin
Shyam Amin
SBSripal Bangalore
Sripal Bangalore

1 January 2018
Verified
Journal Article
Closed access
AVAlexander Volodarskiy
Alexander Volodarskiy
SKSunil Kumar
Sunil Kumar
RPRadoslaw Pracon
Radoslaw Pracon
MSMandeep Sidhu
Mandeep Sidhu
EKEvgeny Kretov
Evgeny Kretov
SBSripal Bangalore
Sripal Bangalore